###### Key messages

-   **What is already known about this subject?**

-   Clinical trials using three different drugs with factor Xa inhibitor activity have been published in atrial fibrillation, in each case compared with warfarin. Some previous meta-analyses, unlike the present one, have included data obtained with a drug with a different mechanism of action.
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-   **What does this study add?**

-   A "class effect" may exist for these drugs in what concerns total mortality and haemorrhagic stroke (both decreased, when compared to warfarin therapy), but not for other outcomes, such as major bleeding and gastrointestinal bleeding. The characteristics of trial design may have played a role in the heterogeneity seen with some outcomes.
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-   **How might this impact on clinical practice?**

-   Clinicians may obtain a clear view on what can be expected when using any of the three drugs under analysis, in patients with atrial fibrillation, when compared to warfarin, and what can be expected from each individual drug and regimen, information to be added to other aspects when considering anticoagulation in this setting.

Introduction {#s1}
============

Atrial fibrillation (AF) is a condition associated with important complications, including stroke.[@R1] Anticoagulation with warfarin leads to a decreased incidence of thromboembolic events in patients with AF.[@R2] [@R3] Warfarin therapy in AF is associated with significant side effects, namely haemorrhagic phenomena. Warfarin use implies INR (international normalised ratio) monitoring, since genetic aspects[@R4] and interactions with food and other drugs are not uncommon. These aspects have resulted in an interest in developing new therapeutic approaches.

New anticoagulant drugs have been presented, with mechanisms of action different from warfarin: dabigatran,[@R5] a thrombin inhibitor, and apixaban,[@R6] rivaroxaban[@R7] and edoxaban,[@R8] as factor Xa inhibitor oral anticoagulant (XOAC) drugs. In what concerns factor Xa inhibitors, the three aforementioned drugs have shown interesting effects in patients with AF, in large clinical trials carried out with warfarin as the comparator drug.[@R6]

The purpose of the present report was to compare the major results obtained with each of the three XOAC drugs, not only by analysing the clinical trial data, but also by carrying out a meta-analysis, aiming at the possible identification of patterns common to the different XOAC therapies. Since edoxaban was used in two different dosages in the Engage-AF Timi 48 trial, four different sets of data are in fact available. Data obtained with dabigatran were not used, since the drug has a different mechanism of action, and the inclusion of dabigatran data would lack biological meaning.

Methods {#s2}
=======

Data were independently retrieved by two authors from the original reports: Aristotle,[@R6] Rocket-AF[@R7] and Engage AF Timi 48[@R8] (data retrieved at study level). 'Intention to treat' data were used whenever available. Meta-analysis was carried out by using the Comprehensive Meta-analysis Software, V.2.0 (Biostat, New Jersey, USA). Random-effects analyses were carried out, given the considerable heterogeneity of the data.[@R9]

For the purpose of the meta-analysis, the data from the two edoxaban arms in the Engage AF trial[@R8] were taken together, since one single warfarin control group existed. Risk ratios and 95% CIs are presented.

The parameters chosen for analysis and also for the meta-analysis were the primary end point (stroke plus systemic embolism for the three studies), total mortality, myocardial infarction, ischaemic stroke, haemorrhagic stroke, major bleeding and gastrointestinal bleeding.

Results {#s3}
=======

A general overview of the three trials is presented in [table 1](#OPENHRT2014000080TB1){ref-type="table"}, including data on the number of patients, primary end point chosen, drug dosage, CHADS2 score of the patients, median age, type of arrhythmia, percentage of INR in therapeutic range for the warfarin group and duration of median follow-up. A significant degree of heterogeneity was seen: different drugs were used in the three trials, with different criteria for patient selection, different times of follow-up, once daily administration for rivaroxaban and edoxaban, versus twice daily for apixaban, two different dosages for edoxaban. The patients under study in the three trials did not have the same degree of risk of thromboembolic events, with different mean values for the CHADS2 score ([table 1](#OPENHRT2014000080TB1){ref-type="table"}).

###### 

General overview of the three trials with factor Xa inhibitors versus warfarin

                                              Aristotle apixaban                                                                                             Rocket-AF rivaroxaban                                                          Engage AF edoxaban
  ------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------
  Total number of patients                    18 201                                                                                                         14 264                                                                         21 105
  Primary end point                           Stroke or systemic embolism                                                                                    Stroke or systemic embolism                                                    Stroke or systemic embolism
  Drug dose (factor Xa inhibitor)             5 mg twice daily; 2.5 mg with two or more of: age ≥80 years, body weight ≤60 kg, serum creatinine ≥1.5 mg/dL   20 mg daily; 15 mg daily in patients with creatinine clearance 30--49 mL/min   Either 60 or 30 mg; half dose if: creatinine clearance of 30--50 mL/min, body weight ≤60 kg, concomitant use of P-glycoprotein inhibitors
  Pretrial risk                               CHADS2 score of 1 or higher (mean of 2.1)                                                                      CHADS2 score of 2 or higher (mean of 3.5)                                      CHADS2 score of 2 or higher (mean of 2.8)
  Median age (years)                          70                                                                                                             73                                                                             72
  INR in therapeutic range (warfarin group)   Median of 66%                                                                                                  Median of 58%                                                                  Median of 68.4%
  Arrhythmia                                  Atrial fibrillation or flutter                                                                                 Non-valvular atrial fibrillation                                               Atrial fibrillation
  Median follow-up                            1.8 years                                                                                                      707 days                                                                       2.8 years
  Aspirin use (%)                             30.5--31.3                                                                                                     36.3--36.7                                                                     28.7--29.7

INR, international normalised ratio.

The major results from the three reports are presented in [table 2](#OPENHRT2014000080TB2){ref-type="table"} and in [figures 1](#OPENHRT2014000080F1){ref-type="fig"}[](#OPENHRT2014000080F2){ref-type="fig"}[](#OPENHRT2014000080F3){ref-type="fig"}[](#OPENHRT2014000080F4){ref-type="fig"}[](#OPENHRT2014000080F5){ref-type="fig"}[](#OPENHRT2014000080F6){ref-type="fig"}--[7](#OPENHRT2014000080F7){ref-type="fig"}.

###### 

Major results of the three trials with factor Xa inhibitors versus warfarin (data are n/N)

                               Aristotle    Rocket-AF   Engage AF                                         
  ---------------------------- ------------ ----------- ------------ ---------- ------------ ------------ ----------
  Primary end point            212/9120\*   265/9081    269/7081     306/7090   296/7035     383/7034     337/7036
  Mortality                    603/9120\*   669/9081    208/7061     250/7082   773/7035     737/7034\*   839/7036
  Ischaemic stroke             149/9120     155/9081    149/7061     161/7082   236/7035     333/7034\*   235/7036
  Haemorrhagic stroke          40/9120\*    78/9081     29/7061\*    50/7082    49/7035\*    30/7034\*    90/7036
  Myocardial infarction        90/9120      102/9081    101/7061     126/7082   133/7035     169/7034     141/7036
  Major bleeding               327/9088\*   462/9052    395/7111     386/7125   418/7012\*   254/7002\*   524/7012
  Gastrointestinal bleeeding   105/9088     119/9052    224/7111\*   154/7125   232/7012\*   129/7002\*   190/7012

\*Labelled as significantly different versus warfarin in the original report.
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![Meta-analysis of three clinical trials with factor Xa inhibitors versus warfarin. Data on gastrointestinal bleeding. Heterogeneity: I²=84.486; p=0.002 (XOAC, factor Xa inhibitor oral anticoagulant).](openhrt2014000080f07){#OPENHRT2014000080F7}

The largest reduction associated with XOAC therapy was seen with haemorrhagic stroke, with a similar pattern for all regimens and meta-analysis showing a risk ratio of 0.488 (95% CI 0.396 to 0.601).

Regarding total mortality, XOAC therapy also showed a favourable pattern for all four regimens, and meta-analysis showed a risk ratio of 0.892 (95% CI 0.840 to 0.947). Apixaban therapy was associated with decreased mortality when compared with warfarin. Interestingly, low-dose edoxaban therapy was also associated with significantly lower values for haemorrhagic stroke and total mortality.

In what concerns the primary end point, stroke plus systemic embolism, apixaban showed a significantly favourable effect, when compared with warfarin, the opposite being observed with a low dose of edoxaban.

With respect to myocardial infarction, a similar pattern was observed, with low-dose edoxaban associated with results in the opposite direction than the other three alternatives, when compared with warfarin; however, none of the values observed reached significance level.

Regarding ischaemic stroke, low-dose edoxaban therapy was associated with a significantly higher number of episodes, when compared with warfarin, unlike the other three regimens.

Major bleeding was lower with apixaban and with both doses of edoxaban, when compared with warfarin, but not with rivaroxaban.

Regarding gastrointestinal bleeding, high-dose edoxaban and rivaroxaban therapies were associated with worse results than warfarin, while low-dose edoxaban had better results.

Discussion {#s4}
==========

Controlled clinical trials are a major method to establish the effects of drugs in humans since, unlike epidemiological studies, clinical trials may have strong internal validity and may establish a nexus of causality.[@R10] However, a better understanding of the effects of drugs frequently occurs only after a given drug is in general use for some years, namely in what concerns the discovery of rare side effects.

The results reported in the three clinical trials with factor Xa inhibitors apixaban, rivaroxaban and edoxaban, compared in each case to warfarin, yielded a relatively clear image on the therapeutic interest of these three drugs in AF. The present comparative analysis of XOAC drugs has shown a significant degree of heterogeneity of effects. Pharmacological differences between drugs could be at play. These drugs, having a narrow therapeutic range, could depend critically on the design of the clinical trials, in what respects the observed effects. Dramatic differences in the effects of edoxaban according to the dose used,[@R8] similar to what had been observed with dabigatran,[@R5] strongly point in the latter direction. In the case of edoxaban in the Engage AF trial, two different dosages of the drug were under study,[@R8] but the low dose of edoxaban was associated with the lowest mortality, possibly in association with the also lowest number of major bleeding events.[@R8]

Four different therapeutic regimens have been studied with XOAC drugs, to be added to further two with dabigatran. Each regimen yielded its own set of effects, and the different sets of effects were in fact quite different. What, if any, are the common characteristics of the effects of XOAC drugs under the regimens studied in patients with AF? The present report attempts to provide an answer to this question.

Seven types of outcomes are under analysis in this report. For some of them, a similar pattern seems to exist for the different XOAC drugs, whereas the same does not seem to happen regarding other outcomes.

The mortality rate was decreased in association with the three XOAC drugs, when compared with warfarin therapy, by about one-tenth. Haemorrhagic stroke also seems to be clearly decreased under these three XOAC drugs, when compared with warfarin. In fact, the incidence of haemorrhagic stroke under the three XOAC drugs was about half the incidence seen under warfarin therapy. These two effects would seem to be associated with factor Xa inhibition therapy.

On the other hand, major bleeding and gastrointestinal bleeding provided two examples regarding which heterogeneity would seem to exist when XOAC drugs are compared with warfarin.

In what concerns the incidence of myocardial infarction, the primary end point (stroke plus systemic embolism) and ischaemic stroke, the situation is less clear. These results are inconsistent with a putative 'group effect' for all the seven parameters under study. The interest of the meta-analysis data would seem to be confined to the end points regarding sets of data consistent with a 'group effect' (the group consisting of apixaban, rivaroxaban and edoxaban). In what concerns end points with data on both sides of the unity line and with at least one significant value, the meta-analytical numerical conclusion would seem to be devoid of any clear biological meaning, given the heterogeneity in the trial conditions, and it would probably be best to evaluate the data from each clinical trial separately.

Ruff *et al*[@R11] published a meta-analysis including the three trials with factor Xa inhibitor drugs and also the thrombin inhibitor, dabigatran, and removing the data obtained with the low drug doses from the main study. The conclusions regarding haemorrhagic stroke and total mortality are similar to the conclusions on these end points now reported; however, different conclusions were reached in other end points, namely gastrointestinal bleeding.

Gastrointestinal bleeding associated with XOAC drugs, in fact, surpassed the figures for warfarin in the case of rivaroxaban and of high-dose edoxaban, drugs used once daily, but not in the trial with twice daily drug use (apixaban) or with low-dose edoxaban. One can speculate that pharmacokinetic aspects/peak intensity of factor Xa inhibition/choice of drug doses/once versus twice daily use may stand behind some of the findings on this topic. In any event, it would certainly not appear that increased gastrointestinal bleeding is a necessary consequence of XOAC drug therapy, when compared with warfarin.

It is yet to be fully understood how these drugs compare with warfarin in 'real-world' situations. Concerns regarding adherence to therapy, possible drug interactions, cost and current absence of antidotes may be taken into consideration when choosing an anticoagulant drug.[@R12]

Study limitations: Data were obtained at study level (from the original publications) meta-analysis of data from the Engage AF trial used aggregate data from patients under the two edoxaban dosages, thus limiting the heterogeneity evaluation presented in the legend of the figures.

In conclusion, apixaban, rivaroxaban and edoxaban have shown interesting effects, when compared with warfarin, in patients with AF. The incidence of haemorrhagic stroke under the three XOAC drugs is about half the incidence seen under warfarin therapy, whereas the mortality rate is also decreased by about one-tenth. No other clear and consistent conclusions concerning a putative 'group effect' can be reached at the present stage.
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